UNS share price going to be $1.2 in 12 months, page-56

The 2Q results show that the ramp still has not really started. The once they start selling devices has long been the real question and even with amgen money coming on board...IMO WILL continue to be an issue in 2016!

After all...

"Having long said that 2013 would be the inflection point for our business, I am pleased to have turned the corner. We are now entering a period of hyper-growth, and expect to generate accelerating, recurring revenue from an expanding base of customers," stated Mr. Alan Shortall, CEO of Unilife.

"Last month, we announced the first in a series of agreements with immediate revenue. This 15-year customization and supply contact for the EZMix dual-chamber syringe is with a U.S. based pharmaceutical company that we expect will generate up to $110 million in cumulative revenue.

"We are getting ready to announce our first major long-term supply contract for the Unifill syringe. This is a significant multi-year commercial supply contract with a major pharmaceutical customer that generates revenue immediately. Negotiations for this agreement are complete and all terms have been agreed upon, with the execution copy now being routed for signature by both parties. I expect this agreement will establish Unilife as one of the leading suppliers of prefilled syringes in our industry.

"With so many transformational agreements generating immediate revenue, we have no intention of doing any secondary stock offering that would cause significant dilution to existing shareholders. We have therefore agreed to preliminary terms with a major U.S. life science financing firm for a debt funding program that we expect to finalize later this month. Combined with the anticipated cash to be generated from new and existing customers, we expect this medium-term debt program to strengthen our balance sheet as we transition into strong and accelerating revenue growth," Mr. Shortall concluded.